The U.S. Food and Drug Administration approved Takeda Pharmaceutical’s (TAK, TKPHF, 4502.T) Mimrylo (rusfertide), a new therapy for adults with polycythemia vera, a rare blood disorder characterized by excess red blood cell production. Elevated red cell counts can thicken the blood, raising the risk of cardiovascular complications such as clots, stroke, and heart attack.
Mimrylo offers a novel treatment approach for patients whose disease is not adequately controlled by existing therapies. It is the first approved therapy for polycythemia vera that mimics hepcidin, a hormone that naturally regulates iron. By limiting iron availability, Mimrylo reduces new red blood cell production and helps maintain healthier red cell levels.
Takeda noted that the open‑label extension of the VERIFY trial is ongoing, and the company will share further findings at upcoming medical conferences. It is also working with regulators outside the United States to potentially broaden Mimrylo’s availability worldwide.
The approval does not affect Takeda’s consolidated financial forecast for the fiscal year ending March 31, 2027.
Takeda closed Friday’s regular trading session at $18.03, unchanged. In after‑hours trading, the stock rose to $18.49, gaining $0.46 or 2.53%.